This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
10. The Chiesi M3 antagonist/PDE4 inhibitor dual pharmacology molecule, compound 92a, is an inhaled compound intended for pulmonary diseases. Both…
molecule
2 years ago ●
1 min read
11. The Venatorx serine _-lactamase inhibitor VNRX-7145 is an orally bioavailable prodrug of the boronic acid-containing inhibitor VNRX-5236, and is…
molecule
2 years ago ●
1 min read
12. The Shionogi beta-lactamase inhibitor (BLI) cyclohexyl ester prodrug, compound 21, is a molecule with an interesting sulfinylamide motif on…
molecule
2 years ago ●
1 min read
The Biogen compound BIO-32546 is a potent (IC50 = 1 nM), selective, oral, non-zinc-binding reversible autotaxin (ATX) inhibitor, and is…
molecule
2 years ago ●
1 min read
14. The Minoryx peroxisome proliferator-activated receptor gamma (PPARg) agonist, leriglitazone, is one of the several metabolites of pioglitazone, a member…
molecule
2 years ago ●
1 min read
The Genentech next generation oral SERD (selective estrogen receptor degrader) and full antagonist, giredestrant (GDC-9545), is a potential best-in-class Ph. III candidate for…
molecule
1 year ago ●
1 min read
Load More
